University of Pittsburgh Medical Center Emergency Department
Pittsburgh, Pennsylvania, 15261, United States
NCT Number: NCT02846649
The objective is to determine feasibility and acceptability of a text message (SMS)-based relapse prevention intervention as measured through: (1) study retention and SMS query completion rates and (2) participant ratings of PIER1 interest, perceived efficacy, and ease of use. Methods: A mixed methods study of adult (age >=18) ED patients who seek treatment for opioids and have evidence of dependence based on Rapid Opioid Dependence Screen (RODS) score of >3 and are being discharged to outpatient (community) resources. All participants receive standard of care in the ED, complete a baseline web survey, are asked to text with us for at least 7 days (up to a max of 28 days) and are asked to complete a follow-up phone call between day 8 and 14. Investigators expect preliminary findings to support a relapse prevention intervention delivered through SMS. Based on feedback from this mixed methods study, investigators plan to test a refined SMS program in a randomized trial.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Not applicable
Pittsburgh, Pennsylvania, 15261, United States
The vast majority of those with opioid dependence do not receive treatment. This may be due to the limited availability of existing treatment programs and to a range of societal and individual-level barriers, including the stigma associated with identifying oneself as a substance user and difficulty attending a treatment program on a regular basis. Technology-based interventions have potential to help address these barriers and to expand access to evidence-based psychosocial treatment. Automated, computer-based interventions have found high user acceptance and utilization and shown promise in treating substance use disorders. The current study will evaluate a text-message-based psychosocial program called PIER1 (Preventing and Interrupting Early Relapse 1) when delivered to treatment-seeking opioid-dependent emergency department (ED) patients. PIER1 is an interactive program based on the Relapse Prevention Model. It is also informed by cognitive behavioral therapy and motivational interviewing.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Daily text message queries with tailored support
Time frame: 7 days
Investigators will report the percentage of SMS queries replied to over 7 days.
Time frame: 7 days
Investigators will report the number of self-reported opioid use occasions.
Time frame: 7 days
Investigators will report the number of self-reported opioid overdoses.
Time frame: 7 days
Investigators will report the median self-reported usefulness rating (0=not at all, 1=somewhat useful; 2=moderately useful; 3=very useful; 4=extremely useful
University of Pittsburgh
Other
Feasibility and Acceptability of Using an Automated Text Messaging Program to Help Prevent Early Relapse Among Treatment-seeking Opioid Dependent Patients Discharged From the Emergency Department
Acronym: PIER1
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06629493
Alcohol Use Disorder (AUD), Alcohol-Related Disorders
Gijón, Principality of Asturias, Spain
View Trial DetailsNCT03866694
Behavior, Chemically-Induced Disorders
Boston, Massachusetts, United States
View Trial DetailsNCT05998005
Behavior, Behavior, Addictive
Bonners Ferry, Idaho, United States
View Trial DetailsNCT01117753
Anxiety Disorder, Anxiety Disorders
Charleston, South Carolina, United States
View Trial Details